Drug Trial Radar · NCT05864846
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Jun 29, 2023
Primary completion
Apr 6, 2026
Study completion Apr 6, 2026
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- May 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
Conditions
- Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Interventions
Cannabidiol Oral Solution [Epidiolex]Drug
100 mg/ml Cannabidiol Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the most problematic behavior Numerical Rating Score (NRS) score within the TAND-SQTime frame: Baseline, Week 13, Week 26, Week 52
- Change in Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders Self-report, Quantified Checklist (TAND-SQ) scoreTime frame: Baseline, Week 13, Week 26, Week 52
- Change in Aberrant Behavior Checklist (ABC) scoreTime frame: Baseline, Week 13, Week 26, Week 52
- Change in Child Behavior Checklist (CBCL) scoreTime frame: Baseline, Week 26, Week 52
- Change in Adult Behavior Checklist (ABCL) scoreTime frame: Baseline, Week 26, Week 52
- Change in Adult Self-Report (ASR) scoreTime frame: Baseline, Week 26, Week 52
- Change in Patient-Reported Outcomes Measurement Information System (PROMIS) domains scoreTime frame: Baseline, Week 26, Week 52
- Change in sleep characteristics using the Children's Sleep Habits Questionnaire (CSHQ)Time frame: Baseline, Week 26
- Change in sleep characteristics using the Pittsburgh Sleep Quality Index (PSQI)Time frame: Baseline, Week 26
- Change in executive function using Behavior Rating Inventory of Executive Function (BRIEF)Time frame: Baseline, Week 26
- Change in caregiver-reported assessment of Quality of Life (QOL) using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM)Time frame: Baseline, Week 26
- Change in caregiver-reported assessment of family functioning using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM)Time frame: Baseline, Week 26
- Change in assessment of QOL using Pediatric Quality of Life Inventory (PedsQL)Time frame: Baseline, Week 26
- Change in caregiver impression of overall severity of symptoms (behavior and seizure control) using the Caregiver Global Impression of Severity (CareGI-S)Time frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in participant impression of overall severity of symptoms (behavior and seizure control) using the Patient Global Impression of Severity (PGI-S)Time frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in clinician impression of overall severity of symptoms (behavior and seizure control) using the Clinician Global Impression of Severity (CGI-S)Time frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Retention RateTime frame: Baseline, Week 13, Week 26, Week 52
- Number of participants considered treatment respondersTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in number of seizure-free daysTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Number of participants experiencing a worsening, no change, or improvement in seizure frequencyTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in ideation score per the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in number of suicide attempts per the C-SSRSTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in ideation score per the Children's C-SSRSTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Change in number of suicide attempts per the Children's C-SSRSTime frame: Baseline, Week 4, Week 13, Week 26, Week 52
- Number of participant inpatient hospitalizations due to epilepsyTime frame: Up to Week 52
- Number of withdrawals due to Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 52
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Yale University School of Medicine
New Haven, Connecticut
University of Florida Health - Department of Neurology
Gainesville, Florida
Nicklaus Children's Health, Miami
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
Minnesota Epilepsy Group
Roseville, Minnesota
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Le Bonheur Children's Hospital
Memphis, Tennessee
University of Texas Health Science Center at Houston - Clinical Research Unit
Houston, Texas
University of Texas Health Science Center - San Antonio
San Antonio, Texas
University of Virginia, Charlottesville
Charlottesville, Virginia
Alberta Children's Hospital
Calgary, Alberta, Canada
BC Children's Hospital
Vancouver, British Columbia, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
The Children's Memorial Health Institute
Warsaw, Poland
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom
Sheffield Children's NHS Foundation Trust
Sheffield, United Kingdom
Evelina London Children's Hospital Guys St Thomas' NHS Foundation Trust, the Guy's Hospital
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.